FDA advisors recommend Eli Lilly Alzheimer's drug donanemab

If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.

Related Keywords

United States ,Japan ,Japanese ,Americans ,Mark Mintun ,Sarah Dolan ,David Risinger ,Eli Lilly ,Drug Administration On ,Critical Path Institute ,Drug Administration ,Leerink Partners ,